Nettoomsättningen i Q1’25 uppgick till 0,1 MSEK (2,0), vilket motsvarade en minskning med 94,5% y.
Stayble Therapeutics redovisade ingen nettoomsättning och en minskad rörelseförlust under det första...
Seasonally weak quarter, but 2025 guidance firm '25e-'27e adj.
Redeye comments on Nanologica following the announcement of the mandatory bid price from its largest...
Redeye updates on Better Collective after Q1-results which saw slightly stronger than expected outco...
Ahead of Solwers' Q1 2025 report, we cut our EBIT estimates by 9-11% for 2025-27 as we expect a some...
Redeye comments on Friday evening’s news from Dala Energi’s AGM, where the voluntary share redemptio...
ExpreS2ion Biotechnologies har ännu inte startat behandling med sitt vaccin i den fas 1-studie på br...
6% organic sales growth y-o-y SaaS momentum drives gross margin uplift.
Redeye comments on Faron’s recent publication in a scientific journal, which provides valuable mecha...
Strong insider commitment signals confidence As expected, Prolight has now announced a rights issue ...
Redeye provides a research update following the Q1 report recently published by Magle.
Redeye updates on GiG after Q1-results which were in line with our expectations and we leave our est...
Redeye’s forecasts and valuation remain unchanged following today’s announced outcome of the TO3 war...
Redeye briefly comments on CTEK’s new financial targets that were presented this morning ahead of to...
The major decrease in sales compared to Q1 2024 was expected.
Redeye comments on the intriguing data from the phase I/II CARMA-study presented by Elicera this mor...
Redeye comments on Jumpgate’s Q1 2025 report, which contained no major surprises and delivered a top...
Redeye comments on GiG’s Q1-results which were largely in line with our forecast where the company s...
